| Item Type | Name |
|
Concept
|
Adenocarcinoma
|
|
Concept
|
Adrenergic beta-Antagonists
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Aminopyridines
|
|
Concept
|
Animals
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Carcinoma
|
|
Concept
|
DNA Damage
|
|
Concept
|
Azacitidine
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Hemangioma
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Leukemia
|
|
Concept
|
Immunoglobulin Fc Fragments
|
|
Concept
|
Cross-Sectional Studies
|
|
Concept
|
Cytarabine
|
|
Concept
|
Disease Susceptibility
|
|
Concept
|
DNA (Cytosine-5-)-Methyltransferases
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Flow Cytometry
|
|
Concept
|
Neutropenia
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
Molecular Biology
|
|
Concept
|
Ovarian Neoplasms
|
|
Concept
|
Prednisone
|
|
Concept
|
Prostatic Neoplasms
|
|
Concept
|
Infertility, Female
|
|
Concept
|
Receptors, Fc
|
|
Concept
|
Recurrence
|
|
Concept
|
Risk Factors
|
|
Concept
|
Quality of Life
|
|
Concept
|
Cadherins
|
|
Concept
|
Spinal Neoplasms
|
|
Concept
|
Humans
|
|
Concept
|
Leukocyte Count
|
|
Concept
|
Linear Models
|
|
Concept
|
Spondylitis, Ankylosing
|
|
Concept
|
United States
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Syndrome
|
|
Concept
|
Clinical Trials, Phase I as Topic
|
|
Concept
|
Germ-Line Mutation
|
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
|
Concept
|
Leukemia, Myeloid
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Proportional Hazards Models
|
|
Concept
|
Antibodies, Antineutrophil Cytoplasmic
|
|
Concept
|
Disease Management
|
|
Concept
|
Matrix Metalloproteinase 1
|
|
Concept
|
Central Nervous System Neoplasms
|
|
Concept
|
Prevalence
|
|
Concept
|
Lymphoma
|
|
Concept
|
Multiple Myeloma
|
|
Concept
|
Leukemia, Myeloid, Acute
|
|
Concept
|
Chi-Square Distribution
|
|
Concept
|
Immunotherapy, Adoptive
|
|
Concept
|
Clinical Trials, Phase II as Topic
|
|
Concept
|
Case-Control Studies
|
|
Concept
|
Connexins
|
|
Concept
|
Endometrial Neoplasms
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Mice, Knockout
|
|
Concept
|
Efficiency, Organizational
|
|
Concept
|
Carcinoma, Endometrioid
|
|
Concept
|
beta Catenin
|
|
Concept
|
Chemoradiotherapy, Adjuvant
|
|
Concept
|
Green Fluorescent Proteins
|
|
Concept
|
Tissue Inhibitor of Metalloproteinase-2
|
|
Concept
|
Matrix Metalloproteinase 9
|
|
Concept
|
Propranolol
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Mice
|
|
Concept
|
Surveys and Questionnaires
|
|
Concept
|
Sarcoma
|
|
Concept
|
Severity of Illness Index
|
|
Concept
|
Thrombopoietin
|
|
Concept
|
Uridine
|
|
Concept
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Survival Analysis
|
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
Workload
|
|
Concept
|
Turkey
|
|
Concept
|
Leukemia, Myelomonocytic, Chronic
|
|
Concept
|
Survival Rate
|
|
Concept
|
Thy-1 Antigens
|
|
Concept
|
Lymphoma, T-Cell
|
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
|
Concept
|
DNA Methylation
|
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Hematologic Neoplasms
|
|
Concept
|
Genome-Wide Association Study
|
|
Concept
|
Activin Receptors, Type II
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Mutation Rate
|
|
Concept
|
Thymocytes
|
|
Concept
|
Tissue Array Analysis
|
|
Concept
|
fms-Like Tyrosine Kinase 3
|
|
Concept
|
Kaplan-Meier Estimate
|
|
Concept
|
Comparative Genomic Hybridization
|
|
Concept
|
Back Pain
|
|
Concept
|
Chromosome Aberrations
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Hematinics
|
|
Concept
|
Lymphoma, Non-Hodgkin
|
|
Concept
|
Magnetic Resonance Imaging
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
Thymus Gland
|
|
Concept
|
World Health Organization
|
|
Concept
|
Idarubicin
|
|
Concept
|
Histiocytic Disorders, Malignant
|
|
Concept
|
Immunophenotyping
|
|
Concept
|
Lymphoma, T-Cell, Peripheral
|
|
Concept
|
Mice, SCID
|
|
Concept
|
Mice, Inbred NOD
|
|
Concept
|
Cost of Illness
|
|
Concept
|
Neoplasm, Residual
|
|
Concept
|
Disease-Free Survival
|
|
Concept
|
CD55 Antigens
|
|
Concept
|
Genetic Predisposition to Disease
|
|
Concept
|
Polymorphism, Single Nucleotide
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Academic Article
|
B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas.
|
|
Academic Article
|
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
|
|
Concept
|
Cell Self Renewal
|
|
Concept
|
Rituximab
|
|
Concept
|
Enhancer of Zeste Homolog 2 Protein
|
|
Concept
|
Nanog Homeobox Protein
|
|
Concept
|
Connexin 26
|
|
Concept
|
Myeloid Cell Leukemia Sequence 1 Protein
|
|
Concept
|
Triple Negative Breast Neoplasms
|
|
Academic Article
|
New Advances and Challenges of Targeting Cancer Stem Cells.
|
|
Academic Article
|
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
|
|
Academic Article
|
No appreciable decrease in fertility in Behçet's syndrome.
|
|
Academic Article
|
Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
|
|
Academic Article
|
From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes.
|
|
Academic Article
|
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
|
|
Academic Article
|
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
|
|
Academic Article
|
Schwachman-Diamond syndrome: Increased risk for autoimmune diseases?
|
|
Academic Article
|
Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase.
|
|
Academic Article
|
Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors.
|
|
Academic Article
|
Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.
|
|
Academic Article
|
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
|